Mouse Anti-KMT2C Recombinant Antibody (CBT2314) (V2LY-0625-LY1178)

Na, F., Pan, X., Chen, J., Chen, X., Wang, M., Chi, P., ... & Chen, C. (2022). KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nature cancer, 3(6), 753-767.

Limberger, T., Schlederer, M., Trachtová, K., Garces de los Fayos Alonso, I., Yang, J., Högler, S., ... & Kenner, L. (2022). KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. Molecular Cancer, 21(1), 89.

Liu, X., Qiu, R., Xu, M., Meng, M., Zhao, S., Ji, J., & Yang, Y. (2021). KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. Breast Cancer Research and Treatment, 189, 347-361.

Mastoraki, S., Balgkouranidou, I., Tsaroucha, E., Klinakis, A., Georgoulias, V., & Lianidou, E. (2021). KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer. Molecular Oncology, 15(9), 2412-2422.

Lavery, W. J., Barski, A., Wiley, S., Schorry, E. K., & Lindsley, A. W. (2020). KMT2C/D COMPASS complex-associated diseases [K CD COM-ADs]: an emerging class of congenital regulopathies. Clinical epigenetics, 12, 1-20.

Larsson, C., Cordeddu, L., Siggens, L., Pandzic, T., Kundu, S., He, L., ... & Sjöblom, T. (2020). Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. Clinical Epigenetics, 12(1), 1-12.

Chen, X., Zhang, G., Chen, B., Wang, Y., Guo, L., Cao, L., ... & Liao, N. (2019). Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomedicine & Pharmacotherapy, 116, 108997.

Fagan, R. J., & Dingwall, A. K. (2019). COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. Cancer letters, 458, 56-65.

Cho, S. J., Yoon, C., Lee, J. H., Chang, K. K., Lin, J. X., Kim, Y. H., ... & Yoon, S. S. (2018). KMT2C mutations in diffuse-type gastric adenocarcinoma promote epithelial-to-mesenchymal transition. Clinical Cancer Research, 24(24), 6556-6569.

Gala, K., Li, Q., Sinha, A., Razavi, P., Dorso, M., Sanchez-Vega, F., ... & Chandarlapaty, S. (2018). KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene, 37(34), 4692-4710.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols